AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed backnews2026-02-10T12:04:05+00:00February 10th, 2026|Endpoints News|
Hengrui, Kailera push obesity pill ahead on promising mid-stage China datanews2026-02-10T12:00:31+00:00February 10th, 2026|Endpoints News|
FDA rejects Regenxbio’s Hunter syndrome gene therapynews2026-02-09T21:15:23+00:00February 9th, 2026|Endpoints News|
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%news2026-02-09T14:15:12+00:00February 9th, 2026|Endpoints News|
Takeda, Iambic sign multiyear R&D deal for AI drug discoverynews2026-02-09T13:00:13+00:00February 9th, 2026|Endpoints News|
#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMSnews2026-02-07T20:15:33+00:00February 7th, 2026|Endpoints News|
Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosisnews2026-02-06T12:00:30+00:00February 6th, 2026|Endpoints News|
Illumina bets on healthcare after Trump administration’s NIH funding disruptionsnews2026-02-06T09:19:24+00:00February 6th, 2026|Endpoints News|
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trialnews2026-02-05T17:15:12+00:00February 5th, 2026|Endpoints News|
Bristol Myers draws pipeline excitement as several data readouts nearnews2026-02-05T15:50:01+00:00February 5th, 2026|Endpoints News|
